Back to Journals » Cancer Management and Research » Volume 6

Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Authors Ho M, Mackey J

Received 13 March 2014

Accepted for publication 14 April 2014

Published 27 May 2014 Volume 2014:6 Pages 253—259


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Maria Y Ho, John R Mackey

Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada

Abstract: The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.

Keywords: toxicity, chemotherapy, adverse events

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]